Perrigo announced that it has received tentative approval from the FDA for its Abbreviated New Drug Application (ANDA) to market over-the-counter (OTC) omeprazole and sodium bicarbonate capsules 20mg/1100mg, the store brand equivalent to Merck’s Zegerid OTC.
Zegerid OTC is a proton pump inhibitor indicated to relieve frequent heartburn.
Perrigo expects to launch the product on the date when market formation occurs.
For more information call (800) 719-9260 or visit www.perrigo.com.
Related Content